RxDoctor Payments Data

Andrea Beatty

Corneal and Contact Management · Shawnee, KSNPI 1093908329

Payments from drug & device makers

What this record shows

Johnson & Johnson Vision Care, Inc. accounts for 73.4% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2019 at $1,308 and has fallen 87.8% since, to $160 in 2025.

$1,771in general payments, 2019–2025

Across 31 payments — averaging $57.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson Vision Care, Inc.$1K
  • LKC Technologies, Inc.$114
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$80
  • Bausch & Lomb Americas Inc.$69
  • Alcon$54
  • Glaukos Corporation$53
  • plus $102 from 5 others

What the payments were for

  • Travel & lodging$90651%
  • Food & beverage$86549%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few corneal and contact management providers in Kansasto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$18,815
Medicare patients
138
Services billed
186

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine26$35,044
Cyclosporine20$17,885
Prednisolone Acetate64$1,754
Loteprednol Etabonate11$859
Latanoprost83$748
Tobramycin-DexamethasoneTobramycin/Dexamethasone11$576
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha32$390
Timolol Maleate25$68
Azithromycin15$34

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis$15$35,04426 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$80$85911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few corneal and contact management providers in Kansason file to place this against a meaningful peer group, so we don't.

Other corneal and contact management in Shawnee

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →